Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tocilizumab - Roche

Drug Profile

Tocilizumab - Roche

Alternative Names: Actemra; ACTPen; Anti-IL-6 receptor antibody - Chugai; Anti-interleukin-6 receptor antibody - Chugai; Atlizumab; HPM-1; MRA; MRA - Chugai; MRA-SC; R-1569; RG-1569; rhPM-1; RO4877533; RoActemra

Latest Information Update: 29 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chugai Pharmaceutical; Osaka University
  • Developer Assistance Publique Hopitaux de Paris; Charite - Universitatsmedizin Berlin; Chugai Pharmaceutical; Hospital for Special Surgery; JW Pharmaceutical; Roche; University Hospital Inselspital; University Hospital Tubingen; University of Bern; University of Pittsburgh
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug hypersensitivity; Giant lymph node hyperplasia; Vasculitis; Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Giant cell arteritis; Giant lymph node hyperplasia; Juvenile rheumatoid arthritis; Rheumatoid arthritis
  • Registered Drug hypersensitivity; Vasculitis
  • Preregistration Adult-onset Still's disease
  • Phase III Osteoarthritis; Systemic scleroderma
  • Phase II Amyotrophic lateral sclerosis; Dermatomyositis; Familial Mediterranean fever; Polymyalgia rheumatica; Polymyositis; Pulmonary arterial hypertension; Schnitzler syndrome
  • No development reported Chronic lymphocytic leukaemia
  • Discontinued Ankylosing spondylitis; Crohn's disease; Multiple myeloma; Pancreatic cancer; Systemic lupus erythematosus

Most Recent Events

  • 26 Nov 2018 Roche announces intention to launch to the single-dose prefilled autoinjector of tocilizumab 162 mg/0.9 mL (ACTPen™) for Giant cell arteritis, Juvenile rheumatoid arthritis and Rheumatoid arthritis in USA in 2019
  • 26 Nov 2018 The US FDA approves single-dose tocilizumab (ACTPen™) prefilled autoinjector for the treatment of Giant cell arteritis, Juvenile rheumatoid arthritis and Rheumatoid arthritis in USA
  • 28 Oct 2018 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, First-line therapy) in Israel (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top